Using AI to predict outcomes of acute pulmonary embolism
Prediction of Adverse Outcome of Acute Pulmonary Embolism by Artificial Intelligence System Based on CT Pulmonary Angiography
This study is trying to see if a new AI tool can help predict complications in patients with acute pulmonary embolism based on their CT scans and other health information.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 2000 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | Shengjing Hospital Academic / other |
| Locations | 1 site (Shenyang, Liaoning) |
| Trial ID | NCT05482269 on ClinicalTrials.gov |
What this trial studies
This observational study aims to develop a predictive tool using artificial intelligence to assess adverse outcomes in patients diagnosed with acute pulmonary embolism based on CT pulmonary angiography. It collects clinical, laboratory, and imaging data from patients upon admission and follows them for 30 days to predict potential complications. Patients are divided into derivation and validation cohorts to create and test a multivariable logistic regression model, comparing its effectiveness to existing risk stratification systems.
Who should consider this trial
Good fit: Ideal candidates are adults aged 18 years and older diagnosed with pulmonary embolism confirmed by CT pulmonary angiography.
Not a fit: Patients who are pregnant, have received reperfusion treatment before admission, or have incomplete data regarding key clinical parameters will not benefit from this study.
Why it matters
Potential benefit: If successful, this tool could significantly improve the prediction of adverse outcomes in patients with acute pulmonary embolism, leading to better clinical management.
How similar studies have performed: While the use of AI in predicting clinical outcomes is an emerging field, similar studies have shown promise in other areas of medicine, indicating potential for success in this approach.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * age of ≥ 18 years and a pulmonary embolism diagnosis based on CT pulmonary angiography Exclusion Criteria: * pregnancy * reception of reperfusion treatment before admission * missing data regarding CT parameters, echocardiography, cardiac troponin I (c-Tn I), and N-terminal-pro brain natriuretic peptide (NT-pro BNP) levels.
Where this trial is running
Shenyang, Liaoning
- Shengjing Hospital — Shenyang, Liaoning, China (Recruiting)
Study contacts
- Principal investigator: Dong Jia — Shengjing Hospital
- Study coordinator: Dong Jia
- Email: jiadong0101@126.com
- Phone: +86-18940252800
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.